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Summary 
Mouse mammary tumor virus  (MMTV)-encoded superantigens  (SAGs) influence the murine 
T  cell repertoire and stimulate  a strong mixed lymphocyte response in vitro.  These SAGs are 
encoded by the open reading frame of the 3' long terminal repeat of MMTV,  termed MMTV 
SAGs. The T cell response to MMTV SAGs is V/3 restricted and requires expression of the class 
II molecules of the major histocompatibility  complex (MHC) on the presenting cells. While 
human T  cells respond to bacterial SAGs, it is not known if human T cells or human MHC 
class II molecules can interact with MMTV SAGs. A fibroblastic cell line expressing the human 
MHC class II molecule HLA-DR1 and the Mtv-7 sag gene encoding Mls-1 was used to stimulate 
human T  cells. We show here that human T  cells efficiently proliferate in response to Mls-1 
presented by HLA-DR1. This T cell response was inhibited by mAbs directed against CD4 or 
MHC class II molecules but not by mAbs specific for CD8 or MHC class I molecules. Moreover, 
the response to Mls-1 was limited to human T cells expressing a restricted set of T cell receptor 
V/3 chains. Human T cells expressing V~12, 13, 14, 15, and 23 were selectively amplified after 
Mtv-7 sag stimulation. Interestingly,  these human V/~s share the highest degree of homology 
with the mouse V~s interacting with Mls-1. These results show a strong evolutionary conservation 
of the structures required for the presentation and the response to retrovirally encoded endogenous 
SAGs, raising the possibility that similar elements operate in humans to shape the T cell repertoire. 
S 
uperantigens  (SAGs)  1 are a new class of Ags that stimu- 
late a large number of human and mouse T cells expressing 
specific variable regions of the TCR/3 chain (1-3). The re- 
sponse of T cells to SAG requires the expression of MHC 
class II molecules on the cell surface of the APCs (1, 4, 5). 
Unlike nominal antigens, SAGs are not processed into pep- 
tides by APCs. Two sets of molecules have been shown to 
exhibit the properties of SAGs. Bacterial toxins expressed by 
Staphylococcus and Streptococcus bacteria stimulate large number 
of T cells after their interaction with MHC class II mole- 
cules. More recently, protein products encoded within the 
3' LTR of mouse mammary tumor virus  (MMTV) were 
shown to be directly associated  with Mls SAG reactivity (6-12). 
In the mouse, molecules of the Mls loci are directly in- 
volved in shaping the TCR repertoire (13-15). Genetic anal- 
ysis of recombinant mouse strains established a direct corre- 
1 Abbreviations used in this paper: MMTV, mouse mammary tumor virus; 
RT,  reverse transcriptase; SAG, superantigen. 
lation  between  endogenous  MMTV  integrants  and  the 
expression of Mls Ags (6-8). Moreover, exogenous MMTVs 
were also shown to be directly responsible for the deletion 
of specific sets of V3s (9-12). Transfection of class II + cells 
with the sag gene of endogenous or infectious MMTVs is 
sufficient  to stimulate T cells  expressing  particular V/3s (16-18). 
Mtv-7 sag encodes Mls-1, which stimulates in vitro and de- 
letes in vivo T cells expressing the murine V/~6, 7, 8.1, and 
9 chains (14, 15,  19). 
Retroviruses of the MMTV family are responsible  for mam- 
mary tumors (20). Recent reports have shown that the SAG 
encoded by infectious MMTV is directly responsible  for mam- 
mary tumors (21). Other reports have suggested a role for 
SAGs in autoimmune diseases and immunodeficiencies both 
in mouse and in human (22-26). While human T cells readily 
respond to bacterial SAGs, little is known about their capacity 
to respond to vitally encoded SAGs. One recent report has 
suggested that the rabies virus nucleoprotein can stimulate 
human T cells in a Vfl-specific fashion (27). It becomes im- 
portant to determine whether human MHC class II mole- 
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retrovirally encoded  SAGs. 
To analyze this question, we have used murine fibroblasts 
expressing  the  human  MHC  class  II molecule  HLA-DR1 
and the Mtv-7 sag Mls-1 to stimulate human T  cells in vitro. 
Specific stimulation  of human  T  cells bearing  a  restricted 
number ofVB gene segments was shown. Moreover, the TCR 
VBs expressed on  the human  T  cells responding  to Mls-1 
exhibited a strong degree of homology to the mouse VBs, 
which  are stimulated  by Mls-1. 
Materials and Methods 
Antibodies.  mAbs against the human TCR B chain used in this 
study were $511 (V/$12.2) (28),  3Dll  (V/~5) (29),  Hut-78 (VB1) 
(O. Kanagawa, personal communication), MX6 (VB8) (29), OT145 
(VB6.7a) (30,  31), MKB-1 (VB9)  (O. Kanagawa, personal com- 
munication),  C1 (VB17) (32)  and MH3-2 (VB5)  (O. Kanagawa, 
personal communication). 
b243 is an anti-HLA-DR mAb, BL4 and OKT4 are anti-human 
CD4 mAbs, W6-32 in an anti-human MHC class I mAb, OKT8 
is an anti-human CD8, and Leu-4 is a human CD3-specific mAb. 
Hybridomas were obtained from American Type Culture Collec- 
tion  (Kockville, MD). 
Human T Cell Purification.  T cells were purified from periph- 
eral  blood  of DR1 +  individuals  using  rosetting  with  SRBC 
(Quelab, Montr6al, Qu6bec, Canada). Briefly, peripheral blood was 
diluted in PBS and underlayered with Ficoll-Hypaque (Pharmacia, 
LKB Biotechnology AB, Uppsala, Sweden). After centrifugation, 
the interface was collected and diluted with an equal volume of 
PBS. Cells were washed and resuspended at 5  x  106 cells/ml in 
PBS. They were then incubated at 1:1  (vol/vol) ratio with FCS 
(Gibco Laboratories, Grand Island, NY) preabsorbed with SRBC 
and 2-aminoethylisothiouronium bromide (Sigma Chemical Co., 
St. Louis,  MO) -treated SRBC (1:20) for 10 min at 37~  Cells 
were then spun down and incubated for an additional I  h on ice. 
The supernatant was aspirated and the pellet was resuspended in 
4 ml of RPMI (Gibco Laboratories) supplemented with 10% FCS 
(Gibco Laboratories). Cells were separated on Ficoll. SRBC within 
the T  cell pellet were lysed with 5 ml of buffer containing 0.15 
M NH4Ct, 9.4 M Na2CO3,  0.1 mM EDTA for 2-5 min at room 
temperature. Cell suspensions were then diluted and washed. The 
Ficoll interface was kept to be used as a source of autologous feeder 
cells. 
The T cell and non-T cell fractions were stained with anti-CD3 
(Leu-4-FITC) and anti-HLA-DR (L-243-bio) mAbs to determine 
the degree of purity. T  cell purity was always >98%,  while the 
non-T cell  fraction contained <20%  of T  cells  as confirmed by 
FACS  |  analysis (Becton Dickinson & Co., Mountain View, CA). 
Transfection of Mtv-7 sag in DAP DRI Fibroblasts.  Fibroblasts 
expressing HLA-DR1 molecules were transfected using the cal- 
cium phosphate precipitation technique  (33) with the Mtw7 sag 
gene cloned into the eukaryotic expression vector pHA~Aprl-neo 
(34). 2 d after transfection, cells were trypsinized and plated at 104 
cells per well in 24-well  plates in the presence of I  mg/ml G418 
(Gibco Laboratories). This selection procedure allowed us to generate 
individual clones of DR1 cells transfected with Mtw7 sag. Northern 
blot analysis was used to confirm Mtv-7 sag expression. Two clones, 
3A5 and 3B2,  were selected  and used in these experiments. 
Human  T  Cell Stimulation with Mtv-7 sag.  Purified human T 
cells were stimulated with DAP DR1 fibroblasts expressing the 
cDNA encoding for the 3' open reading frame (ORF) of Mtv-7 
in the presence or absence of autologous feeder cells. Controls in- 
cluded DR1 cells that had not been transfected with the gene en- 
coding Mtv-7 sag. 6  x  10  s T cells were cultured with mitomycin 
C  (Sigma Chemical Co.) -treated DR1 + or DR1 + Mtv-7 sag + 
DAP fibroblasts (100 #g/ml of mitomycin C  for 107 cells,  1 h at 
37~  at  different  effectorAtimulator  ratios  in  96-well  round- 
bottomed plates.  Cultures were carried out at 37~  5% CO2 in 
complete RPMI supplemented with 10% FCS. Usually, 5  x  10  s 
autologous irradiated feeder cells (5,000 rad) were added in each 
well. After 3 d of coculture, 1/~Ci of [3H]Tdr (DuPont Co.-New 
England Nuclear,  Boston,  MA) was added for 18 h.  Cells were 
harvested and  [3H]Tdr  incorporation  was determined  using a 3 
plate counter (Pharmacia, LKB Biotechnology AB). 
mAb  Inhibition of Mls.I  Stimulation.  6  x  10  s T  cells  were 
cocultured with 2  x  10  s mitomycin C-treated DR1 + Mls-1 + 3A5 
DAP cells in the presence of 5  x  10  s autologous irradiated  (5,000 
tad) feeder cells, mAbs against CD4 (BL-4), CD8 (OKT8), HLA-DR 
(b243),  or MHC class I (W6-32) were added at 2, 0.2, and 0.02 
/zg/ml. T cell proliferation was measured after 72 h incubation by 
[3H]Tdr incorporation as described above.  All of the mAbs used 
in these experiments were purified on protein G columns (Phar- 
macia, LKB Biotechnology AB). 
T Cell Expansion after Mls-1 or PHA Stimulation.  Mls-1 stimu- 
lation was performed as described in the previous section at an 
effector/stimulator ratio of 3:1. For PHA stimulation, 106 T cells 
were cultured with 2  x  10  s irradiated autologous feeder cells and 
1/~g/ml PHA (Wellmark Diagnostics, Guelph, Ontario, Canada) 
in a final volume of 2 ml in 24-well plates. After 3-4 d of stimula- 
tion, recombinant human Ib2 (10 U/ml) (Cetus Corp., Emoryville, 
CA) was added.  T  cells were expanded in recombinant IL-2 for 
10-14 d. 
Cytofluorometric Analysis tithe V/~ Repertoire after Mls-1 or PHA 
Stimulation.  Two-color flow cytometric analysis was performed, 
10 d after stimulation, using CD4- and TCR V/S-specific  mAbs. 
Briefly, 2.5  x  10  s calls were first incubated with saturating con- 
centrations of anti-V~ mAbs for 30 rain at 4~  in complete medium. 
Cells were then washed with PBS and stained using a 1:100 dilu- 
tion of goat anti-mouse Ig coupled to PE (GAMPE; Southern Bin- 
technology Associates, In~, Birmingham, AL). Cells were incubated 
for 30 rain at 4~  and washed in PBS. Normal mouse serum was 
then added for 15 rain at 4~  to block the GAMPE antibodies. 
Cells were washed and counterstained with PlTC-conjugated anti- 
CD4  mAb (OKT4-FITC,  1/200  dilution)  for 30  min  at 4~ 
Stainings were analyzed on a FACScan |  (Becton Dickinson & Co.) 
using two-color cytofluorometry. 104 live cells were gated using 
forward and 90  ~ light scatter. Results are expressed on a four-decade 
logarithmic scale for each two-color histogram. 
PCR Primers.  PCR primers were synthesized on an oligonu- 
cleotide synthesizer (Applied Biosystem Canada Inc., Mississanga, 
Ontario, Canada). Primer sequences  of the TCR VB-specific oli- 
gonucleotides are listed in Fig. 1. The G-C content was m40-60%. 
The specificity of the different Vfl oligonucleotides was determined 
by crosshybridization.  The oligonucleotide sequences of the primers 
for the TCR oL and fl chain constant regions are: 3' Cfl, 5' TCT 
ACC CCA GGC CTC GGC GCT GAC GAT 3'; 3' Ccr  5' AGC 
CGC AGC GTC ATG AGC AGA TTA AAC CCG 3'; 5' Cc~, 
5' GCA TGT GCA AAC GCC TTC AAC AAC AGC 3'. 
PCR Analysis of the Expressed Vfls Repertoire.  T  cells  were 
pelleted for RNA extraction 10 d after stimulation and expansion 
in recombinant II.-2 (Cetus Corp.). Total RNA was prepared using 
RNAzol (Cinna-Biotecx, Houston, TX). 10/~g of total RNA was 
boiled 2-5 rain and used to synthesize the first-strand cDNA by 
adding  5 #g of random hexamer oligonucleotides  and 60 U  of 
Moloney leukemia virus reverse transcriptase (RT) (Life Sciences, 
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presence of RNAse inhibitor, 1/zM dNTPs (Pharmacia, LKB Bio- 
technology AB) in a buffer containing 10 mM Tris-HC1 (pH 8.3), 
6  mM  MgClz,  and 40 mM  KC1 at 420C  for 45 min.  RT  and 
nucleotides were then added and followed by a second incubation 
period of 45 min.  The RT reaction was stopped by heating the 
mixture at 65ac for 10 min. The cDNA preparation was precipi- 
tated  and used  for  PCR  VB  analysis.  The  different  VBs  were 
amplified using a 5' VB-specific primer and a common 3' CI3 primer. 
5' and 3' Ccr primers  were included in each reaction tube as in- 
ternal  control. The 3' C~ and 3' Cc~ primers  were radiolabeled 
with 7-[32p]ATP  (30,000 Ci/mmol);  50 pmol of oligonucleotide 
was incubated with 4/d  of 7-[32p]ATP  and 20 U  of T4 poly- 
nucleotide  kinase  (Pharmacia,  LKB  Biotechnology AB)  in  the 
manufacturer's buffer for 1 h at 37~  Free nucleotides were elimi- 
nated using a G-25 superfine Sephadex column. PCR amplification 
was performed with 25 pmol of 5' VB, 5' C(x, and a mixture of 
cold and radiolabeled 3' CB (22 pmol of cold and 3 pmol of radiola- 
beled oligonucleotide) and 3' Cc~ (25 pmol of cold and 0.3 pmol 
of radiolabeled oligonucleotide). The PCR reaction was carried out 
using 200/xM dNTPs, 2 U ofTaq polymerase (Perkin-Elmer Corp., 
Norwalk, CT) in lx  Taq buffer (10 mM Tris-HC1, pH 8.3, 50 mM 
KCI,  1.5  mM  MgC12,  and 0.01%  [wt/vol]  gelatin)  in  a  final 
volume of 100/~1.  Amplification was performed  for 30 s at 94~ 
45 s at 55ac,  and 60 s at 72~  for 25 cycles.  Half the volume of 
each PCR reaction was loaded and separated on a 10% PAGE con- 
taining 7 M urea. Gels were exposed overnight on Phosphorlmager 
screens (Molecular Dynamics, Inc., Sunnyvale, CA). Quantitation 
of the radioactive  signal for each  VB was carried out using the 
Imagequant  software  and the  Phosphorlmager  (Molecular  Dy- 
namics,  Inc.). 
Name  Sequence  Spec~cl~ 
5'  3* 
V~ 1  AGA TTC TGG ACT CAC ACA AAC CCC ARA GCA C  V~ I.  1,  V~  1.2 
5'  3' 
V~ 2  GAG CTG GGT TAT CTG TAA GAG  V~ 2.1 
5"  3" 
V~ 3  AGA TGT GAA ACT ARC CCA GAG CTC3GAG ATA T  V~ ~.i,  V~ 3,2 
5' 
V~ 4  CAA GTC GAT AGC CAA GTC ACC ATG  V~ 4. 
5'  3' 
V~ 5.1  CTC CCC TAT CTC TGG GCA TAG AG  V~  5.1,  V~ 5.4 
5'  3' 
V~ 5.2  CTC TCC TAA GTC TGG GCA TGA  V~  5.2 
5"  3' 
V~ 6  AGG TGC TGG AGT CTC CCA GAC CCC CAG TA  V~ 6.i,  V~ 6.3 
5*  3' 
V~ 7  CAT GGG AAT GAC AAA TAA GAA GTC  V~ 7.1 
5'  3' 
V~ 8  AGA TGC TGG AGT TAT CCA GTC ACC CCG CCA TGA  V~ 8.1,  Y~ 8.3 
5"  3' 
V~ 9  AAC GAC AAG TCC ATT AAA  V~ 9.1 
5  ~  3' 
V~10  AGA CAC CAA GGT CAC CCA GAG ACC TAG ACT T  V~10.1,  V~10.2 
5'  3' 
V~11  AGA AGC TGA CAT CTA CCA GAC CCC AAG ATA C  V~11.1 
5"  3' 
V~I2  AAA TGC TGG TGT CAC TCA GAC CCC AAA ATT C  V~12.3 
5'  3' 
V~I3  GTT GGT GCT GGT ATC ACT GA  V~I3.1 
5'  3' 
V~I4  AGT TAA CAG TGA CTT GTT CTC AGA A  V~I4.1 
5  =  3' 
V~I5  AGA TGC TGA TGT TAC CCA GAC CCC AAG GAA  V~15.1 
5*  3' 
V~16  GAC TGT GAC TCT GAG ATG TGA C  V~16.1 
5"  3" 
V~17  AGA TGG TGG AAT CAC TCA GTC CCC AAA GTA C  V~I7.1 
5'  3' 
V~17b  ACC CAA GAC ACC TGG TCA GGA GGA GG  V~17.1 
5'  3' 
V~18  AAA TGC CGG CGT CAT GCA GAA CCC AAG ACA C  V~IS.I 
5'  3' 
V~19  ACA TGC  CAA AGT CAC ACA GAC TCC AGG ACA TTT  V~I9.1 
5'  3' 
V~20  ACA TGC CAA AGT CAC ACA GAC TCC AGG ACA TTT  V~20.1 
5'  3' 
V~21  GAG TGT GGC TTT TTG GTG CAA  V~21.1* 
5'  3' 
V~22  TGG GAC AGG AAG TCA TCT TGC  V~22.1 
5"  3" 
V~23  GAC AGC TGA TCA AAG AAA AGA  V~23.1 
5'  3' 
V~24  AGG TTA CCC AGT TTG GAA AGC  V~24.1" 
Figure  1.  Description and sequence of human TCR V~8-specific oligo- 
nucleotide primers. *From reference 44. 
~.esults 
Mls-l-expressed DR1 + DAP Fibroblasts Stimulate the Prolifer- 
ation of Human  T  Cells.  To determine  whether  human T 
cells are able to respond to Mtv-7 SAG Mls-1,  the Mtv-Tsag 
gene was  transfected  into DR1 +  DAP  fibroblasts.  Expres- 
sion of Mtv-7 sag transcripts was confirmed by Northern blot 
analysis  (Subramanyam,  M.,  B.  McLellan,  N.  Labrecque, 
R.-P. Sekaly, and B. T. Huber, manuscript submitted for pub- 
lication).  The  human  MHC  class  II  molecule  HLA-DR1 
efficiently presented the Mtv-7 SAG to murine T cell hybrid- 
omas  expressing  the  appropriate  TCR  VBs  (VB6 and 8.1) 
(Subramanyam,  M.,  et al., manuscript  submitted for publi- 
cation). These DAP cells were then used to stimulate purified 
populations  of human T  cells  obtained  from  HLA-DR1 + 
individuals. Fig.  2 A  shows a 30-fold increase in [3H]Tdr in- 
corporation 72 h after the addition of purified human T cells 
to mitomycin  C-treated  DR1 §  Mls-1 + DAP  transfectants. 
T cells cultured in the presence of DAP cells expressing only 
DR1 did not show such an increase. Proliferation, after 72 h 
of  cocuhure,  was  dependent  on  the  number  of  DR1 + 
Mls-1 +  APCs.  Significant  proliferation,  fivefold  over DAP 
DR1  stimulation,  was still observed at the lowest effector/ 
stimulator  cell  ratio  tested  (10:1). 
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Figure  2.  Stimulation of human purified T cells by DR.1 + Mls-1 + 
DAP cells. (.4 and B) Proliferative response of human T cells stimulated 
with DR1 § (DAP cells transfected with HLA-DR1) and DR1 + Mls-1 + 
3A5 (DAP cells transfected with HLA-DR1 as well as mtv-7 sa  c gene). 
Stimulation was performed in the presence (.4) or absence (/3) of 10  s ir- 
radiated autoiogous feeder cells at different effector/stimulator ratios. (C) 
Kinetics of human T cell response to Mls-1. Proliferative response of human 
T cells stimulated with DR1*  alone, DR1 § Mls-I + 3A5 (DR1 mt~7 
3A5), or DR1 § Mls-1 + 3B2 (DR1 m~-7 3B2) DAP cells (effector/stimu- 
lator ratio, 1:3) in the presence of 10  s irradiated autoiogous feeder cells, 
measured after 48 and 72 h. Bars represent the mean of triplicate values 
of [3H]Tdr incorporation. 
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lator ceils for both aUogeneic and xenogeneic responses (35). 
For this purpose, human autologous irradiated non-T cells 
were added to the coculture, which increased human T  cell 
proliferation by at least twofold (see Fig. 2 B). The kinetics 
of the human T cell response to Mls-1 are comparable to what 
is observed when the same human T cells are stimulated with 
bacterial SAGs (data not shown). After 48 h of stimulation 
the T  cell response was very low (fivefold), however, a con- 
siderable increase (30-fold) is observed by 72 h  (Fig.  2 C). 
Similar  kinetics  were observed when  two different DR1 + 
Mls-1 + DAP transfectants  were used (Fig.  2  C). 
Presentation of Mtv-7 SAG to Human T Cells Is Inhibited by 
Anti-CD4 and Anti-HLA-DR but Not by Anti-CD8 and Anti- 
MHC Class I mAbs.  In the murine system, the Mls response 
is blocked by antibodies directed to MHC class II molecules 
(36, 37). To further confirm the similarity of the human T 
cell response to Mls-1, mAb inhibition experiments were per- 
formed. Anti-HLA-DR mAb (L-243) completely inhibited 
T  cell  proliferation.  This  inhibition  occurred  in  a  dose- 
dependent  fashion,  as shown in Fig. 3, confirming  the re- 
quirement  for  MHC  class  II  molecules  for  an  Mtv-7 
SAG-specific response. Murine T  cells responding to Mls-1 
are mostly CD4 + , and CD4-specific mAbs significantly in- 
hibit this response (5). The human T cell response to DR1 + 
Mls-1 §  cells  was  inhibited  in  a  dose-dependent  manner 
when anti-CD4  (BL-4) mAb was added to the culture (see 
Fig. 3). However, T cell proliferation was still observed (four- 
fold over background) at the highest concentration of CD4- 
specific mAb (2/xg/ml),  suggesting that CD4-  T  cells were 
also responding to Mls-1. Recent reports have demonstrated 
that  murine  CD8 § T  cells can also proliferate in response 
to Mls-1 (38, 39). Interestingly, anti-CD8 (OKTS) mAb does 
not affect the T cell response (Fig. 3), as was previously shown 
to be the case for murine CD8 + T cells responding to Mls-1 
(H. R. McDonald, personal communication). As predicted, 
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Figure  3.  mAb inhibition of Mls-1 stimulation.  Mls-1 stimulation  of 
human T  cells is inhibited  by anti-CD4 and anti-MHC class II mAbs, 
but not by anti-CD8 and anti-MHC class I mAbs. T cells were stimulated 
with DR1 + Mls-1 + 3A5 DAP cells at an effector/stimulator  ratio of 1:3 
in the presence or absence of anti-CD4 (BL4) anti-CD8 (OKT8)-, anti- 
HLA-DR (I.,243)-, or anti-MHC class I  (wr-32)-specific mAbs.  mAb 
concentrations  ranged between 0.02 and 2/xg/ml. Bars represent the mean 
of triplicate  values of 13H]Tdr incorporation. 
anti-MHC class I (W6-32) mAb had no effect on Mls-1 stim- 
ulation of human T cells (Fig. 3). These results further confirm 
the parallel  between human and murine T  cell responses to 
retroviral  SAGs. 
Mls-1 Presentation by DR1 + DAP Fibroblasts to Human  T 
Cells  Increases the  Number  of  TCR  Vf112-expressing  T 
Cells.  The T  cell response to bacterial and retroviral SAGs 
is restricted  to T  cells  expressing only specific  sets of V/~ 
regions. To confirm that  the response of human T  cells to 
Mtv-7 sag was characteristic of a SAG response, human T cells 
responding to Mls-1 presented by DR1 + DAP were stained 
with a panel ofTCR V/~-specific mAbs. Human T cells were 
purified from peripheral blood of DR1 + individuals to avoid 
an allogeneic response. Figs. 4 and 5 represent the results of 
the cytofluorometric analysis of the V/$ usage after stimula- 
tion with PHA, DR1 + DAP, DR1 + Mls-1 + 3A5 DAP, and 
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Figure  4.  Cytofluorometric analysis of TCR V~ usage by human T 
cells in response to Mls-1 presented by DR1 + DAP APCs. T cells were 
stained  with  a  panel  of human  VB-specific mAbs,  followed  by  goat 
anti-mouse Ig antiserum  (PE conjugated),  and then counterstained  with 
an anti-CD4-specific mAb (FITC conjugated) (OKT4). For simplification 
only contour graphs  for CD3, VB12, and VB6.7a are shown.  Contour 
graphs represent VB expression on CD4 § and CD4- after PHA (A-C), 
DR1 + (D-F), DR1 § Mis-1 + 3A5 (G-/), and DR1 + Mls-1 + 3B2 stim- 
ulation (J-L).  The percentage  of CD4+  (top right) and CD4- (top left) 
are indicated.  104 viable cells, gated by light scatter, were accumulated 
for each contour graph. Results are illustrated on a four-decade logarithmic 
scale. 
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Figure 5.  Selective expansion of 
human T cells expressing the TCR 
Vf112 region after  Mls-1  stimula- 
tion. T cells stimulated with PHA 
or Mls-1 were kept  in culture for 
10-14 d in the presence of I1,2 and 
stained with the various VB-specific 
mAbs,  as described in Fig. 4. Per- 
centages of T cells expressing each 
V/3 in four different experiments are 
shown.  The I-ILA type of the in- 
dividuals  was:  A1,  w33;  B14, 
w55; Cw3, w8, DR1,-;-; DQwl; 
A32, 33; B14, 35; Cw4, wS, DR1, 
4;  w53;  DQwl,  w3;  A1,  3;  B7, 
13;  Cw6,  w7;  DR1,  7,  w53, 
DQwl, w2. 
DR1 + Mls-1 + 3B2 DAP. A similar profile in VI3 usage was 
observed when T  cells were stimulated with PHA (Fig. 4, 
A-C) or with DR1 + fibroblasts (Fig.  4, D-F). For simplifi- 
cation only the CD3, V1312, and V136.7 stainings are shown 
in Fig. 4. Most if not all the V/3s were expressed at similar 
levels when purified T  cells were stimulated with PHA or 
cocultured with DAP DR1 cells. Moreover, there was little 
difference in the VI3 profile in PHA-stimulated cells before 
IL-2 expansion  (T cells were stained with the same mAbs 
36 h after PHA stimulation)  and after 10-14 d after expan- 
sion with IL-2 (data not shown). In contrast, flow cytometric 
analysis of VBs expressed in human T  cells stimulated with 
two independent clones of DR1 + Mls-1 + DAP transfectants 
(Fig. 4, G-I and J-L) showed a significant  increase in CD4 + 
V1312 + cells  and  in  CD4-VI312 + cells  (10-fold),  This  in- 
crease in Vl312-expressing  cells was accompanied by a decrease 
in the representation  of the other TCR Vl3s analyzed (Fig. 
4  and  5). 
This selective expansion of human T cells expressing TCR 
V/312 was reproducible in four separate experiments  using 
two  different  clones  of DR1 +  Mls-1 +  DAP  transfectants 
(see Fig. 5). The increase in V/312-expressing T cells ranged 
between 3- and 10-fold in these experiments.  There was no 
detectable increase in any of the other V/3s analyzed in these 
four experiments, strongly confirming the specificity of the 
V1312 response.  Fig.  6  illustrates  the  number  of VB12 + 
CD4 +  and  VI312+CD4 -  cells responding  to  the  two in- 
dependently derived DR1 + Mls-1 + DAP transfectants.  Both 
CD4 +  and  CD4-  V/312 + cells  proliferated  to  the  DR1 + 
Mls-1 + clones (Fig.  6), confirming  previous results in the 
mouse. In three separate experiments the increase in CD4 § 
T  cells was always higher  than  the one observed in CD4- 
T  cells.  This  increase  in  CD4-  T  cells  was never greater 
than sixfold, while as previously mentioned,  CD4 +Vf112 + 
cells were increased by up to  10-fold. 
This relative increase in Vt312 + cells  was also accompa- 
nied by a highly significant increase in the absolute number 
of T  cells.  Hence, while T  cells  cocultured together  with 
DR1 + DAP cells and IL-2 proliferated marginally (threefold 
increase in cell number), there was a reproducible and strong 
proliferation to both DR1 + Mls-1 + transfectants  (10-33-fold 
increase in cell number).  This increase in cell number was 
almost parallel to the one observed in T cells stimulated with 
PHA (10-35  fold). 
Selected V~s Are Amplified after Mls-I Stimulation as Deter- 
mined by PCR Analysis of the TCR Repertoire.  Flow cyto- 
metric analysis  indicated that  >90%  of T  cells responding 
to DR1 + Mls-1 + fibroblasts in IL-2-expanded cultures ex- 
pressed the CD3 molecule on their surface.  Since the total 
sum of Vfls expressed, as determined by flow cytometry, did 
not  reflect the number  of CD3 + cells observed, this  sug- 
gested that other Vfls are responding to Mls-1. To further 
characterize the Vfls expressed by the T  cells responding to 
DR1 + Mls-1 + DAP cells, a quantitative PCR analysis of the 
20 
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Figure 6.  CD4 + and CD4- V1312 T cells respond  to DR1 + Mls-1  + 
DAP cells. The percentage  of total V312 +  , CD4 + V/312  + , and CD4- 
V1312 + T  cells obtained  in three different  experiments  after  PHA and 
Mls-1 stimulation was determined by cytofluorometric analysis as described 
in Fig.  4.  Histogram of 104 live cells was obtained  on a FACscan  | 
1739  Labrecque et al. whole VB repertoire was performed. Oligonucleotides specific 
for the 24 known V3 families were used to analyze the ex- 
pressed VB repertoire (see Fig. 1). This assay was carried out 
on PHA-stimulated T  cells and on T  cells cocultured with 
the two independently derived DR1 + Mls-1 + transfectants. 
Fig.  7 A  shows the PCK V~ profile of T  cells  stimulated 
with PHA and IL-2. Most of the V/3s are expressed. A different 
picture emerges from the analysis of the V~ repertoire of T 
cells  responding  to  the  DR1 +  Mls-1 +  DAP  clones,  3A5 
(Fig.  7 B) and 3B2 (Fig.  7 C~  Autoradiograms of the quan- 
titative PCR analysis clearly show a strong amplification of 
a restricted number of VBs (V~12,  13,  14,  15,  16,  and 23) 
only in samples of T  cells,  stimulated with DR1 + Mls-1 + . 
Most of the other VBs, which were present in PHA-stimulated 
cells, were not amplified, demonstrating the preferential and 
specific expansion of T cells expressing the above-mentioned 
VBs. Quantitative PCR analysis confirms results illustrated 
in  Figs.  4-6,  showing  the increase  in  relative numbers  of 
VB12 + cells. A 3-10-fold increase in the relative expression 
of the  above VBs  was  noted  after  coculture  with  DR1 + 
Mls-1 + cells. 
Amplification of V~12, 13, 14, 15, and 23 was consistently 
seen in three different experiments using human T cells purified 
from three different DR1 +  donors  (see Fig.  8,  B,  D,  and 
F) when compared with PHA (Fig. 8, A, C, and E). A 3-10- 
fold increase  in the relative expression of the different VBs 
was noted in three different individuals tested. Moreover, the 
two DR1 § Mls-1 § DAP clones reproducibly yielded a selec- 
tive  amplification  of V312,  13,  14,  15,  and  23  (data  not 
shown). 
Discussion 
In this report, we demonstrate specific stimulation of human 
T  cells to the Mtv-7 sag presented by DR1 + DAP fibroblasts. 
This T  cell stimulation  was due to Mls-1 recognition since 
no T cell proliferation was seen in response to untransfected 
DR1 +  fibroblasts.  T  cell responses  were enhanced  by the 
presence of autologous feeder cells. These cells may provide 
additional cytokines that help T cell responses. The response 
of human T cells bears all the characteristics of an Mls-1 stim- 
ulation (1); it is inhibited by anti-CD4 and anti--class II mAbs 
but not by anti-CD8  and  anti-class  I  mAbs.  Both  CD4 + 
and  CD4-  T  cells  respond  to  DR1 +  Mls-1 + DAP  cells; 
however,  unlike  antigen-specific  responses,  proliferation  of 
both T cell subsets is inhibited by DR-specific mAhs, while 
mAbs to CD8  and to MHC class  I  do not  have an effect. 
Similar observations have already been described in human 
and murine T  cell responses to bacterial SAGs (1, 40).  The 
strong primary proliferative response of the human  T  cells 
to DR1 + Mls-1 + cells further  confirms the parallel with  a 
SAG response. 
The hallmark  of the response to a SAG is the TCK V3 
restriction of the responding T  cells.  Indeed,  the human T 
cell response to Mtv-7 SAG presented by the human MHC 
class II molecules, HLA-DK1, is restricted to T cells expressing 
a limited set of V~s, further confirming the parallel between 
human  and murine T  cell responses to this retrovirally en- 
coded SAG. Cytofluorometric analysis,  using a restricted set 
of TCR V~-specific mAbs, has  enabled us to demonstrate 
that  CD4 +  VB12 +  and  CD4-  V~12 +  cells  respond  to 
DR1 + Mls-1 + cells. Quantitative PCK analysis of the TCK 
Figure  7.  PCR analysis of the TCR VB usage of human 
T cells in response to Mtt,-7  sag transfected in DK1 + DAP 
fibroblasts. Electrophoresis  of the PCK VB reactions  of 
human  T  cells stimulated  with:  (.4)  PHA; (/3) DR1 + 
Mls-1 + 3A5 DAP cells, and (C) DK1 + Mls-1 + 3B2 DAP 
cells. Each lane represents  the amplification  of a family 
of a particular TCR VB gene, using a specific oligonucle- 
otide in 5' and a 32p-labeled TCR-B constant  region oli- 
gonudeotide in Y. The TCK Cot was amplified in each 
reaction  as an internal  control. Gels were exposed for 2 
d. These autoradiograms  are representative of three sepa- 
rate  experiments. 
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Figure  8.  Relative percentage of TCR V3 
usage as determined by PCR analysis. PCR V/~ 
reactions were subjected  to electrophoresis  and 
exposed  on a Phosphorlmager screen  overnight. 
Radioactive signals were quantitated using a 
Phosphorlmager. The raw PCR value is rep- 
resented as ratio of the numerical value of the 
V3 to the Ca signal (100x). The sum of raw 
PCR values  for each V3/Cc~  combination  was 
determined and used to calculate the relative 
percent of  each V~. Represented  is the relative 
percent of TCR V3 usage after stimulation 
with PHA (A, C, and E) or DR1 + Mls-1  + 
3B2 DAP (B, D, and F). A and B, C and D, 
and E and F represent pairwise quantitative 
PCR values of PHA- and Mls-l-stimulated  cells 
from three different individuals. 
repertoire confirmed that V312 cells were expanded in T cells 
stimulated  by DR1 +  Mls-1 +  cells.  Moreover,  other  V3s 
were also significantly expanded, i.e., V313, 14, 15, and 23. 
As previously mentioned,  the expansion ranged from 3- to 
10-fold and was reproducible in three different individuals 
irrespective of their MHC haplotype. Interestingly, V312'and 
V~17 were amplified by PCR only in two of the three indi- 
viduals  tested.  Since  the  V317  family  contains  only  one 
member, it is possible that polymorphisms in V317 genes 
analogous to the polymorphisms previously described for the 
murine V38 and V317 genes (41, 42) confer to some indi- 
viduals the capacity to respond  to Mls-1. 
The human TCR V3 gene products that recognize Mls-1 
share the highest homology with the mouse V~ chains known 
to be selectively expanded in Mls-1 stimulation (V36, 7, 8.1, 
and  9).  The  human  V/312  and  13 genes share  ,o70% ho- 
mology in nucleotide sequences with the mouse V38.1 gene, 
while the human V315 gene is 70% homologous to the mouse 
V37 gene (43).  Only the human V~23 gene product does 
not possess strong homology (44-56%) with Mls-l-reactive 
murine  V3s  (44).  The  homology of the  human  V~s  re- 
sponding to Mls-1 with other murine V3s that do not re- 
spond  to Mls-1  varies  between 40 and  55%  (43). 
The CDR4 of the TCR VB chain encompasses critical 
residues for the Mls-1 response (42, 45). Residues 68-76 of 
the CDR4 loop are predicted to lie on a B-pleated sheet away 
from the CDR.1-3, which are involved in conventional an- 
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tigen recognition. Critical residues for Mls-1 recognition in- 
clude amino acids 73 and 74, as shown from V3 polymoro 
phisms in wild mice and by site-directed mutagenesis studies 
(41, 42, 45). Moreover, residue N74 in an Mls-l-nonreactive 
V3 chain carries a potential glycosylation site. Interestingly, 
none of the Mls-l-reactive human V3s have potential glycosy- 
lation sites in the CDR4. A consensus was derived that dearly 
shows that two residues, $68 and R69, are conserved in 13 
of 14 Mls-l-reactive V~s.  A third highly conserved amino 
acid (F75) is present  in almost  all other VB sequences.  In 
contrast,  only  7  of 38  Mls-l-nonreactive  V3s  bear  these 
residues.  The  human  V~23,  which  in  our  experiments 
responds very efficiently to DR1 Mtv-7 sag fibroblasts, does 
not carry these two residues in its CDR.4 sequence.  Since 
only one V~/23 sequence is published so far, it is likely that 
polymorphisms in this V3 gene could modify the reported 
VB23 sequence and conferring reactivity of V323 to Mls-1. 
The results presented here clearly indicate that human T 
cells carry all the structural features required for an efficient 
response to routine retrovirally endogenous encoded SAGs. 
Moreover, this response involves similar mechanisms to those 
required for the response of murine T  cells to Mls-1.  The 
ability of human T  cells to respond to the Mtv-7 SAG and 
the efficient presentation of this SAG by human MHC class 
II molecules suggest the possibility that the human genome 
may contain such SAGs. Several reports have suggested poly- 
morphisms within the human VB locus at the genomic level using Southern blots and VB-specific probes (30,  46,  47). 
Some of these polymorphisms have been associated with dis- 
ease (48).  Using human T  cell stimulation with Mls-1,  it 
will be interesting to verify if the presence of polymorphisms 
or lack thereof in the coding sequence of V~/s is correlated 
with the response to viral SAGs. Such a demonstration would 
provide functional evidence for the role of polymorphisms 
within the TCR VB genes in the deletion of self-reactive 
V~s or in the association  of specific sets of TCR V/3s with 
autoimmune diseases. Indeed, V~14 has been associated in 
one study with rheumatoid arthritis (22), while other groups 
have failed to observe  such a correlation (49-51).  It is pos- 
sible that polymorphisms in the VB14 gene could confer to 
certain individuals the capacity to respond to SAGs encoded 
by pathogens involved in rheumatoid arthritis. Our experi- 
ments provide a model that could be used to identify such 
functional polymorphisms in TCR VB chains. 
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